Daily Ards Research Analysis
Three studies refine ARDS science and practice: a mechanistic study identifies MKRN2-driven p53 ubiquitination as a protective pathway against epithelial apoptosis; a preclinical trial shows blocking the CCL2-CCR2 axis fails to control inflammation despite transient monocyte reduction; and a multicenter COVID-19 ARDS cohort finds prone ventilation improves oxygenation without mortality or LOS benefit, and adjunct IV vasodilators/NMBA add no outcome advantage.
Summary
Three studies refine ARDS science and practice: a mechanistic study identifies MKRN2-driven p53 ubiquitination as a protective pathway against epithelial apoptosis; a preclinical trial shows blocking the CCL2-CCR2 axis fails to control inflammation despite transient monocyte reduction; and a multicenter COVID-19 ARDS cohort finds prone ventilation improves oxygenation without mortality or LOS benefit, and adjunct IV vasodilators/NMBA add no outcome advantage.
Research Themes
- Epithelial apoptosis control via p53 ubiquitination in ARDS
- Reassessing monocyte recruitment blockade (CCL2-CCR2 axis)
- Prone ventilation and adjunct therapies in COVID-19 ARDS
Selected Articles
1. MKRN2 attenuates LPS-induced apoptosis in lung epithelial cells via ubiquitination-mediated p53 degradation.
Using LPS-induced ARDS models, the authors show that MKRN2 overexpression reduces inflammation, ROS, mitochondrial injury, and apoptosis by promoting p53 ubiquitination and degradation; MKRN2 knockdown worsens injury. Transcriptomics and Co-IP/ubiquitination assays mechanistically link MKRN2 to p53 pathway regulation, positioning MKRN2 as a candidate target to limit epithelial injury.
Impact: Provides mechanistic evidence that modulating epithelial apoptosis via MKRN2-p53 ubiquitination can attenuate lung injury, advancing targetable biology in ARDS.
Clinical Implications: While preclinical, the MKRN2-p53 axis suggests a tractable pathway to protect the alveolar epithelium. Future pharmacologic or gene-based modulators of MKRN2 could complement lung-protective ventilation in ARDS.
Key Findings
- MKRN2 overexpression alleviated LPS-induced lung injury in vivo and in vitro by reducing cytokines, ROS, improving mitochondrial ultrastructure, and suppressing apoptosis.
- MKRN2 silencing aggravated inflammatory injury and apoptosis under LPS exposure.
- Co-IP and ubiquitination assays showed MKRN2 directly binds p53 to promote its ubiquitination and degradation; transcriptomics supported modulation of the p53 apoptotic pathway.
Methodological Strengths
- Multi-system experimental approach with in vivo and in vitro LPS models, combining histology, TUNEL, flow cytometry, ELISA, and electron microscopy.
- Mechanistic validation through transcriptome sequencing, co-immunoprecipitation, and ubiquitination assays linking MKRN2 to p53 regulation.
Limitations
- Preclinical LPS-induced models may not capture the heterogeneity of human ARDS etiologies.
- No validation in human tissues; safety, specificity, and off-target effects of MKRN2 modulation were not assessed.
Future Directions: Validate the MKRN2–p53 axis in human ARDS specimens and primary alveolar epithelium; develop small-molecule or gene-based MKRN2 modulators; test efficacy across diverse injury models (acid, ventilator-induced, bacterial).
The complex pathogenesis of acute respiratory distress syndrome (ARDS) underscores the therapeutic potential of targeting lung epithelial cell apoptosis. Makorin ring finger protein 2 (MKRN2), functioning as an E3 ubiquitin ligase, plays a critical role in regulating cell proliferation and apoptosis by specifically recognizing and promoting the degradation of p53. However, the precise mechanisms by which MKRN2 contributes to ARDS progression remain poorly understood. In this study, we employed adenovirus-mediated gene delivery, siRNA interference, and overexpression plasmid transfection to manipulate MKRN2 expression levels. LPS was used to induce both in vivo and in vitro models of ARDS. Histopathological changes in lung tissue and mitochondrial ultrastructure were examined using HE staining and transmission electron microscopy. Inflammatory factors, reactive oxygen species (ROS), and apoptosis rates were quantified using ELISA and flow cytometry. Cell apoptosis was further validated using TUNEL assay. The expression levels of MKRN2, p53, and associated apoptotic proteins were evaluated by real-time fluorescence quantitative PCR, immunofluorescence, and western blotting. Transcriptome sequencing was performed to elucidate the regulatory role of MKRN2 on the p53 pathway, while Co-immunoprecipitation (Co-IP) and ubiquitination assays were used to confirm the direct interaction between MKRN2 and p53. Our results showed that MKRN2 overexpression significantly alleviated LPS-induced lung injury both in vivo and in vitro models, as evidenced by reduced inflammatory factor release, decreased ROS production, improved mitochondrial morphology, and suppressed apoptosis, primarily through downregulation of the pro-apoptotic factor p53. In contrast, MKRN2 silencing exacerbated these injuries. Transcriptome analysis further supported that MKRN2 modulates apoptosis via the p53 signaling pathway, and Co-IP experiments confirmed that MKRN2 promotes the ubiquitination and subsequent degradation of p53. Collectively, these findings suggest that MKRN2 exerts protective effects against LPS-induced lung tissue injury by targeting p53 for ubiquitin-mediated degradation.
2. Pharmacological inhibition of the CCL2-CCR2 axis fails to reduce inflammation in a rat model of acute lung injury.
In a rat HCl/LPS acute lung injury model, local CCL2-neutralizing antibody or CCR2 antagonist transiently reduced monocyte influx at 24 h but failed to sustain reduced infiltration or diminish inflammation at 72 h. Although CCR2 antagonism prevented increased alveolar permeability, neither intervention improved lung damage or function, arguing against single-axis monocyte blockade as a viable anti-inflammatory strategy.
Impact: Provides well-controlled negative evidence that challenges the therapeutic premise of targeting the CCL2-CCR2 axis in early ARDS, informing drug development to avoid ineffective monotherapies.
Clinical Implications: CCR2/CCL2 inhibitors alone are unlikely to control lung inflammation in ARDS; combination, timing-optimized, or pathway-redundancy-aware approaches should be prioritized before clinical translation.
Key Findings
- CCL2 antibody and CCR2 antagonist reduced bronchoalveolar monocyte infiltration at 24 hours post HCl/LPS injury.
- At 72 hours, neither treatment sustained reduced monocyte influx nor significantly alleviated alveolar or lung inflammation.
- CCR2 antagonism prevented increased alveolar permeability, but neither intervention improved lung damage or function.
Methodological Strengths
- Time-resolved assessments at 24 and 72 hours using a combined HCl/LPS injury model with local intrapulmonary delivery.
- Parallel testing of ligand neutralization (CCL2-Ab) and receptor blockade (CCR2-Ant) to interrogate the axis at two levels.
Limitations
- Single species and injury paradigm may limit generalizability across ARDS etiologies.
- Dose optimization, combination strategies, and broader functional outcomes were not extensively evaluated.
Future Directions: Test multi-target or staged interventions accounting for pathway redundancy; extend to large-animal models and assess long-term outcomes; investigate downstream signaling and compensatory chemokine networks.
New therapeutic approaches are needed to regulate inflammation and control monocyte recruitment in acute respiratory distress syndrome (ARDS). Excessive monocyte influx into the alveolar space can exacerbate lung damage, worsening patient outcomes. Delaying or reducing monocyte recruitment into the alveoli space after the injury has been proposed as a strategy to balance the inflammatory response and mitigate lung damage. In the present study, we assessed the possible role of the CCL2-CCR2 axis as a therapy for controlling acute lung injury after the initial neutrophil-driven influx. We administered a CCL2-antibody (CCL2-Ab) or a CCR2-antagonist (CCR2-Ant) locally into the lung following lung injury induced by HCl/LPS instillation. Our results show that after 24 h, both treatments transiently reduced monocyte infiltration into the bronchoalveolar space. After 72 h, neither CCL2-Ab nor CCR2-Ant sustained a reduced monocyte infiltration or significantly alleviated alveolar or lung inflammation. CCR2-Ant prevented an increase of alveolar permeability, but neither of both treatments, CCL2-Ab nor CCR2-Ant, improved lung damage or function. Our findings indicate that blocking the CCL2-CCR2 axis to control monocyte trafficking at early stages of lung injury is insufficient to control inflammation or prevent disease progression. These results highlight the complexity of ARDS pathophysiology and suggest that alternative strategies may be required to effectively modulate monocyte-driven lung inflammation.
3. Impact of proning with and without inhaled pulmonary vasodilators and neuromuscular blocking agents in COVID acute respiratory distress syndrome.
In 114 mechanically ventilated patients with moderate to severe COVID-19 ARDS, prone ventilation improved oxygenation (P/F) but did not reduce mortality or LOS, and VV-ECMO use was similar. Adding inhaled vasodilators and/or neuromuscular blockers to proning yielded no primary outcome benefit, despite trends to improved compliance.
Impact: Real-world multicenter data clarify that proning primarily improves oxygenation without survival benefit and that adjunct inhaled vasodilators/NMBA add no measurable outcome gains, guiding resource use and trial design.
Clinical Implications: Use prone ventilation for oxygenation in COVID-19 ARDS, but avoid reflexive adjunct IV vasodilators/NMBA for outcome improvement; prioritize enrollment in prospective trials to define subgroups that might benefit.
Key Findings
- Prone position ventilation was associated with a significant and sustained increase in P/F ratio, without mortality or VV-ECMO benefit.
- Adjunct inhaled vasodilators and/or neuromuscular blockers with proning did not improve hospital or ICU LOS or mortality compared with proning alone.
- Proned patients had worse baseline respiratory parameters and SOFA scores; ICU and hospital LOS were longer in the proned group.
Methodological Strengths
- Multicenter retrospective cohort with predefined subgroups and serial lung mechanics assessed over 7 days.
- Real-world evaluation during the COVID-19 pandemic, reflecting pragmatic practice patterns.
Limitations
- Retrospective design with significant baseline imbalances and potential confounding by indication.
- Sample size (N=114) limits power to detect mortality differences and subgroup effects.
Future Directions: Conduct prospective randomized trials to test adjunct therapies with proning, optimize timing/dose, and identify phenotypes most likely to benefit.
BACKGROUND: A major cause of mortality in the coronavirus disease 2019 (COVID-19) pandemic was acute respiratory distress syndrome (ARDS). Currently, moderate to severe ARDS induced by COVID-19 (COVID ARDS) and other viral and non-viral etiologies are treated by traditional ARDS protocols that recommend 12-16 hours of prone position ventilation (PPV) with neuromuscular blocking agents (NMBA) and a trial of inhaled vasodilators (IVd) if oxygenation does not improve. However, debate on the efficacy of adjuncts to PPV and low tidal volume ventilation persists and evidence about the benefits of IVd/NMBA in COVID ARDS is sparse. In our multi-center retrospective review, we evaluated the impact of PPV, IVd, and NMBA on outcomes and lung mechanics in COVID ARDS patients with moderate to severe ARDS. AIM: To evaluate the impact of PPV used alone or in combination with pulmonary IVd and/or NMBA in mechanically ventilated patients with moderate to severe ARDS during the COVID-19 pandemic. METHODS: A retrospective study at two tertiary academic medical centers compared outcomes between COVID ARDS patients receiving PPV and patients in the supine position. PPV patients were divided based on concurrent use of ARDS adjunct therapies resulting in four subgroups: (1) PPV alone; (2) PPV and IVd; (3) PPV and NMBA; and (4) PPV, IVd, and NMBA. Primary outcomes were hospital and intensive care unit (ICU) length of stay (LOS), mortality, and venovenous extracorporeal membrane oxygenation (VV-ECMO) status. Secondary outcomes included changes in lung mechanics at 24-hour intervals for 7 days. RESULTS: Total 114 patients were included in this study. Baseline respiratory parameters and Sequential Organ Failure Assessment scores were significantly worse in the PPV group. ICU LOS and LOS were significantly longer for patients who were proned, but no mortality benefit or difference in VV-ECMO status was found. Among the subgroups, no difference in primary outcomes were found. In the secondary analysis, PPV was associated with a significant improvement in arterial oxygen partial pressure (PaO CONCLUSION: In mechanically ventilated patients diagnosed with moderate to severe COVID ARDS, PPV and PPV with the addition of IVd produced a significant and sustained increase in P/F ratio. The combination of PPV, IVd and NMBA improved compliance however this did not reach significance. Mortality and LOS did not improve with adjunct therapies. Further research is warranted to determine the efficacy of these therapies alone and in combination in the treatment of COVID ARDS.